In-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination Strategies

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Galatas, Beatriz ^a,b   Nhamussua, Lidia ^a   Candrinho, Baltazar ^c   Mabote, Lurdes ^a   Cisteró, Pau ^b   Gupta, Himanshu ^b   Rabinovich, Regina ^b   Menéndez, Clara ^a,b   MacEte, Eusebio ^a,c   Saute, Francisco ^a   Mayor, Alfredo ^a,b   Alonso, Pedro ^a,b   Bassat, Quique ^a,b,d   Aide, Pedro ^a,c  

^a Manhiça Health Research Center   (Mozambique)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c MINISTRY OF HEALTH   (Mozambique)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE;

ADULT; ASYMPTOMATIC INFECTION; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; ISOLATION AND PURIFICATION; MALARIA FALCIPARUM; MALE; MOZAMBIQUE; PATHOGENICITY; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIMALARIALS; ASYMPTOMATIC INFECTIONS; CHLOROQUINE; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; MALE; MOZAMBIQUE; PLASMODIUM FALCIPARUM; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85018276748     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01365-4     Document Type: Article

References (41)

1. Awasthi, G., Satya Prasad, G. B. & Das, A. Pfcrt haplotypes and the evolutionary history of chloroquine-resistant Plasmodium falciparum. Memorias do Instituto Oswaldo Cruz 107, 129-134, doi: 10.1590/S0074-02762012000100018 (2012).
2. Bruce-Chwatt, L. J. Resistance of P. falciparum to chloroquine in Africa: True or false? Trans R Soc Trop Med Hyg 64, 776-784, doi: 10.1016/0035-9203(70)90022-2 (1970).
3. Harinasuta, T., Suntharasamai, P. & Viravan, C. Chloroquine-resistant falciparum malaria in Thailand. Lancet 2, 657-660 (1965).
4. World Health Organization. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies. Geneva (2006).
5. Babiker, H. A., Hastings, I. M. & Swedberg, G. Impaired fitness of drug-resistant malaria parasites: Evidence and implication on drug-deployment policies. Expert review of anti-infective therapy 7, 581-593, doi: 10.1586/eri.09.29 (2009).
6. Djimde, A. et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344, 257-263, doi: 10.1056/NEJM200101253440403 (2001).
7. Kublin, J. G. et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187, 1870-1875, doi: 10.1086/jid.2003.187.issue-12, doi:JID30387 [pii]10.1086/375419 (2003).
8. Mita, T. et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. The American journal of tropical medicine and hygiene 68, 413-415 (2003).
9. Takechi, M. et al. Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. Trop Med Int Health 6, 429-434, doi: 10.1046/j.1365-3156.2001.00735.x, doi:tmi735 [pii] (2001).
10. Frosch, A. E. et al. The return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis, doi:jiu216 [pii]10.1093/infdis/jiu216 (2014).
11. Mwanza, S. et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malaria journal 15, 584, doi: 10.1186/s12936-016-1637-3 (2016).
12. Mohammed, A. et al. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malaria journal 12, 415, doi: 10.1186/1475-2875-12-415, doi:1475-2875-12-415[pii]10.1186/1475-2875-12-415 (2013).
13. Mwai, L. et al. Chloroquine resistance before and after its withdrawal in Kenya. Malaria journal 8, 106, doi: 10.1186/1475-2875-8-106, doi:1475-2875-8-106 [pii]10.1186/1475-2875-8-106 (2013).
14. Laufer, M. K. et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355, 1959-1966, doi: 10.1056/NEJMoa062032, doi:355/19/1959 [pii]10.1056/NEJMoa062032 (2006).
15. Laufer, M. K. et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PloS one 7, e42284, doi: 10.1371/journal.pone.0042284 (2012).
16. Mayor, A. G. et al. Prevalence of the K76T mutation in the putative Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene and its relation to chloroquine resistance in Mozambique. J Infect Dis 183, 1413-1416, doi: 10.1086/jid.2001.183.issue-9, doi:JID001261 [pii]10.1086/319856 (2001).
17. Raman, J. et al. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One 6, e25992, doi: 10.1371/journal.pone, 0025992PONE-D-11-14300 [pii] (2011).
18. Thomsen, T. T. et al. Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. The American journal of tropical medicine and hygiene 88, 536-541, doi: 10.4269/ajtmh.12-0525 (2013).
19. Abacassamo, F. et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 9, 200-208, doi: 10.1046/j.1365-3156.2003.01182.x (2004).
20. White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial agents and chemotherapy 41, 1413-1422 (1997).
21. Galatas, B. et al. A prospective cohort study to assess the micro-epidemiology of Plasmodium falciparum clinical malaria in Ilha Josina Machel (Manhica, Mozambique). Malaria journal 15, 444, doi: 10.1186/s12936-016-1496-y (2016).
22. Tiago, Armindo Daniel, Calú, Nurbai, Caupers, Paula & Mabunda, Samuel. Normas de Tratamento da Malária em Mocambique (2011).
23. Planche, T. et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 65, 599-602 (2001).
24. Mayor, A. et al. Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malaria journal 8, 9, doi: 10.1186/1475-2875-8-9 (2009).
25. Taylor, S. M. et al. A quality control program within a clinical trial Consortium for PCR protocols to detect Plasmodium species. Journal of clinical microbiology 52, 2144-2149, doi: 10.1128/jcm.00565-14 (2014).
26. World Health Organization. Methods and techniques for clinical trials on antimalarial efficacy: Genotyping to identify parasite populations (2008).
27. World Health Organization. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization, http://www.emro.who.int/rbm/publications/protocolwho.pdf (2003).
28. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Available at http://www.who.int/malaria/publications/atoz/9789241597531/en/(accessed 25/02/2014). (WHO, 2009).
29. Bretscher, M. T. et al. The distribution of Plasmodium falciparum infection durations. Epidemics 3, 109-118, doi: 10.1016/j.epidem.2011.03.002 (2011).
30. Eckhoff, P. Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings. Am J Trop Med Hyg 88, 817-827, doi: 10.4269/ajtmh.12-0007 (2013).
31. Felger, I. et al. The dynamics of natural Plasmodium falciparum infections. PloS one 7, e45542, doi: 10.1371/journal.pone.0045542 (2012).
32. World Health Organization. Eliminating malaria (2016).
33. Galatas, B., Bassat, Q. & Mayor, A. Malaria Parasites in the Asymptomatic: Looking for the Hay in the Haystack. Trends in parasitology 32, 296-308, doi: 10.1016/j.pt.2015.11.015 (2016).
34. White, N. J. The parasite clearance curve. Malaria journal 10, 278, doi: 10.1186/1475-2875-10-278 (2011).
35. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. (WHO, 2008).
36. Mvumbi, D. M. et al. Assessment of pfcrt 72-76 haplotypes eight years after chloroquine withdrawal in Kinshasa, Democratic Republic of Congo. Malaria journal 12, 459, doi: 10.1186/1475-2875-12-459 (2013).
37. Cortese, J. F., Caraballo, A., Contreras, C. E. & Plowe, C. V. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186, 999-1006, doi: 10.1086/jid.2002.186.issue-7, doi:JID020423 [pii] 10.1086/342946 (2002).
38. Vieira, P. P., das Gracas Alecrim, M., da Silva, L. H., Gonzalez-Jimenez, I. & Zalis, M. G. Analysis of the PfCRT K76T mutation in Plasmodium falciparum isolates from the Amazon region of Brazil. J Infect Dis 183, 1832-1833, doi: 10.1086/jid.2001.183.issue-12, doi:JID010159[pii] 10.1086/320739 (2001).
39. Zalis, M. G., Pang, L., Silveira, M. S., Milhous, W. K. & Wirth, D. F. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: Evidence for quinine resistance. The American journal of tropical medicine and hygiene 58, 630-637 (1998).
40. Volkman, S. K., Cowman, A. F. & Wirth, D. F. Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 92, 8921-8925, doi: 10.1073/pnas.92.19.8921 (1995).
41. Nosten, F. & White, N. J. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77, 181-192 (2007).